Nu-Med Plus (NUMD) Shareholder's Equity Growth (3y) (2014 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Nu-Med Plus | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -62.67% |
| Sep 30, 2025 | 1.44% |
| Jun 30, 2025 | 0.05% |
| Mar 31, 2025 | -7.53% |
| Dec 31, 2024 | -17.57% |
| Sep 30, 2024 | -42.95% |
| Jun 30, 2024 | -382.85% |
| Mar 31, 2024 | -42.32% |
| Dec 31, 2023 | -32.26% |
| Sep 30, 2023 | -37.42% |
| Jun 30, 2023 | -31.63% |
| Mar 31, 2023 | 37.14% |
| Dec 31, 2022 | 44.59% |
| Sep 30, 2022 | 3.80% |
| Jun 30, 2022 | 7.01% |
| Mar 31, 2022 | 5.60% |
| Dec 31, 2021 | -67.83% |
| Sep 30, 2021 | -33.14% |
| Jun 30, 2021 | 59.49% |
| Mar 31, 2021 | 122.95% |
| Dec 31, 2020 | 89.95% |
| Sep 30, 2020 | 70.18% |
| Jun 30, 2020 | 84.14% |
| Mar 31, 2020 | -115.61% |
| Dec 31, 2019 | 56.30% |
| Sep 30, 2019 | -30.47% |
| Jun 30, 2019 | -36.29% |
| Mar 31, 2019 | 3.98% |
| Dec 31, 2018 | 26.06% |
| Sep 30, 2018 | 42.61% |
| Jun 30, 2018 | 48.79% |
| Mar 31, 2018 | 50.75% |
| Dec 31, 2017 | 26.19% |
| Sep 30, 2017 | 41.56% |
| Jun 30, 2017 | -32.78% |
| Mar 31, 2017 | -29.07% |
| Dec 31, 2016 | -229.28% |
| Sep 30, 2016 | 2.12% |
| Jun 30, 2016 | 76.55% |
| Mar 31, 2016 | -25.39% |
| Dec 31, 2015 | -591.28% |
| Dec 31, 2014 | -2,792.14% |